Af­fimed lays off around 50 staffers as it brings com­bo NK cell ther­a­py to PhII

Af­fimed on Tues­day an­nounced that it had laid off a quar­ter of its staff, or rough­ly 50 peo­ple, in April, join­ing a slew of oth­er biotech com­pa­nies that have let em­ploy­ees go over the past year.

The Ger­man NK cell biotech said the lay­offs were need­ed to help fund three clin­i­cal pro­grams that are cur­rent­ly in ear­ly-stage stud­ies. “The bulk of the re­duc­tions have there­fore come from oth­er ar­eas of the or­ga­ni­za­tion – dis­cov­ery, pre­clin­i­cal, and some ad­min­is­tra­tive roles,” an Af­fimed spokesper­son told End­points News in an email.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters